Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Share:
Related PFE
Pfizer Earnings: What The Street And The Crowd Expect
Swedish Orphan Biovitrum AB Confirms Receipt of Preliminary and Conditional Non-binding Proposal for Acquisition of All Shares Issued by Company
Notable earnings before Tuesday's open (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Latest Ratings for PFE

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Mar 2015Deutsche BankMaintainsBuy
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...